Bybit Web3 Lists Eight New Tokens, Supports Direct Trading with USDT, USDC, SOL, BBSOL
The newly listed tokens are:
Ava AI (AVA)
TROLL (TROLL)
The Spirit of Gambling (Tokabu)
Housecoin (House)
unstable coin (USDUC)
Uranus (URANUS)
PYTHIA (PYTHIA)
Illusion of Life (SPARK)
Bybit Web3: Efficient Integration
With the new Bybit Web3, users do not need to juggle multiple external wallets, top up gas tokens, or navigate clunky DeFi interfaces. Users can now buy and sell these tokens directly using USDT, USDC, SOL, or BBSOL from their Unified Trading Account (UTA) — instantly, securely, and without any setup hassle.
Proceeds from token sales are automatically credited to the user's UTA, ensuring a seamless flow of liquidity between centralized and decentralized markets.
This efficient integration delivers the speed and convenience of a centralized exchange combined with the innovation and opportunities of Web3.
Bybit Web3 already supports a growing roster of trending Solana-based assets, giving traders access to early-stage projects and emerging market opportunities.
#Bybit / #TheCryptoArk
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit PressFor media inquiries, please contact: media@bybit.comFor updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM
The GnRH inhibitor market is shifting toward more convenient, patient-focused treatments, driven by oral therapies such as ORGOVYX and YSELTY. As the pipeline continues to grow and indications expand, this drug class is poised for broader clinical use and is likely to play a key role in the future of hormonal suppression in oncology and women's health. LAS VEGAS, Aug. 13, 2025 /PRNewswire/ — DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Endometriosis, fibroids, prostate cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging GnRH receptor antagonists, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the GnRH Receptor Antagonists Market Report As per DelveInsight's analysis, the total market size of GnRH receptor antagonists in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Endometriosis, fibroids, prostate cancer, and others. Leading GnRH receptor antagonist companies, such as Debiopharm, Tiumbio, Antev, and others, are developing novel GnRH Receptor Antagonists that can be available in the GnRH receptor antagonist market in the coming years. Some of the key GnRH receptor antagonists in the pipeline include Debio 4326, Merigolix (TU2670), Teverelix, and others. In May 2025, TiumBio and Daewon Pharmaceutical completed Phase II clinical trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids with positive results. In March 2025, Kissei initiated the Phase III Clinical Trial for the GnRH Antagonist 'Linzagolix' indicated for Endometriosis in Japan. In February 2025, Kissei submitted New Drug Application (NDA) for 'linzagolix' indicated for Uterine Fibroids in Japan. In the EU, linzagolix received marketing authorization for uterine fibroids in June 2022. Discover which indication is expected to grab the major GnRH receptor antagonists market share @ GnRH Receptor Antagonists Market Report GnRH Receptor Antagonists Market Dynamics The GnRH receptor antagonists market is witnessing steady growth driven by advancements in therapeutic applications across a range of hormone-related disorders. These antagonists function by directly inhibiting GnRH receptors in the pituitary gland, thereby suppressing the release of LH and FSH. This mechanism provides a rapid and reversible suppression of sex hormones such as testosterone and estrogen, making them effective alternatives to GnRH agonists, which are associated with an initial hormone surge. Key indications for GnRH receptor antagonists include prostate cancer, endometriosis, uterine fibroids, and assisted reproductive technologies (ART). One of the significant drivers of market expansion is the growing prevalence of hormone-sensitive cancers, particularly prostate cancer in men and endometriosis or uterine fibroids in women. The increasing demand for therapies with improved safety profiles and faster onset of action has created a favorable environment for GnRH antagonists. Moreover, recent product launches such as RELUGOLIX (marketed as ORGOVYX for prostate cancer and MYFEMBREE for uterine fibroids) and ELAGOLIX (marketed as ORILISSA for endometriosis and ORIAHNN for fibroids) have gained regulatory approvals and demonstrated commercial success, further validating the therapeutic potential of this class. Additionally, the market is benefiting from a broader shift towards oral therapies. Unlike older GnRH agonists, many of the newer antagonists are available in oral formulations, improving patient adherence and convenience. This factor is particularly significant in chronic indications where long-term management is necessary. The preference for non-invasive treatment options among patients and providers is reshaping treatment paradigms and expanding the reach of GnRH antagonists beyond hospital settings to outpatient care. However, the market also faces certain challenges. Cost of therapy remains a barrier in several regions, particularly in low- and middle-income countries, where access to advanced hormonal therapies is limited. Furthermore, competition from alternative treatment modalities such as aromatase inhibitors, progestins, and surgical interventions can restrict market penetration in some indications. Intellectual property protection, regulatory requirements, and long development timelines can also impact new entrants and biosimilar competition. In the coming years, continued R&D in expanding the therapeutic use of GnRH antagonists, including potential applications in breast cancer, male infertility, and transgender hormone therapy, is likely to support further market growth. Strategic collaborations, licensing deals, and increasing investments by pharmaceutical companies in reproductive health and oncology are expected to drive innovation and market competitiveness. Overall, the GnRH receptor antagonists market is positioned for sustained growth, underpinned by clinical efficacy, patient-centric delivery formats, and expanding disease awareness. GnRH Receptor Antagonists Treatment Market The introduction of oral GnRH antagonists, known for their rapid onset of action, is reshaping treatment approaches for several prevalent gynecologic and oncologic conditions such as endometriosis, uterine fibroids, and prostate cancer. Over the past decade, the GnRH inhibitor market has undergone a significant transformation, moving from injectable formulations to more convenient oral therapies. Initially, the market was led by FIRMAGON, an injectable GnRH antagonist approved in 2008 for advanced prostate cancer. However, a major turning point came in 2020 with the approval of ORGOVYX by Sumitomo Pharma—the first oral GnRH antagonist for prostate cancer. ORGOVYX marked a clinical advancement by eliminating the testosterone flare linked with GnRH agonists and improving patient convenience by removing the need for injections. Its rapid adoption in androgen deprivation therapy (ADT) highlighted a growing preference for oral options. Another significant development was the approval of YSELTY (linzagolix) in 2022 by the EMA for treating uterine fibroids and endometriosis. Developed by Theramex and Kissei, YSELTY extended the use of GnRH antagonists into women's health, offering a once-daily oral therapy with customizable suppression levels to help mitigate long-term estrogen deficiency effects. This approval further validated the use of oral GnRH inhibitors beyond oncology and underscored their expanding role in broader therapeutic areas. Learn more about the GnRH receptor antagonists @ GnRH Receptor Antagonists Analysis Key Emerging GnRH Receptor Antagonists and Companies Key players in the GnRH receptor antagonist market include Tiumbio (Merigolix), Antev (Teverelix), Debiopharm (Debio 4326), and others. Debio 4326 is an innovative, injectable, and biodegradable formulation of triptorelin, designed to provide extended-release over 12 months for managing central precocious puberty (CPP). Its key advantage lies in significantly reducing injection frequency, thereby easing the treatment experience for children with this rare condition. Developed based on positive efficacy and safety data from existing 1-, 3-, and 6-month triptorelin products, this new version aims to enhance long-term adherence and minimize the emotional and physical stress on both children and their caregivers. Debio 4326 is currently undergoing a Phase 3 clinical trial across North and South America to assess its efficacy and safety. Teverelix is a long-acting, injectable GnRH antagonist formulated using a novel microcrystal technology that addresses the known safety limitations of earlier GnRH antagonist treatments for prostate cancer. With favorable injection site tolerance and a six-week dosing schedule, Teverelix is positioned to offer better patient compliance and improved treatment outcomes. Beyond prostate cancer, it also holds potential for treating benign prostate hyperplasia (BPH), acute urinary retention (AUR), endometriosis, and uterine fibroids. In January 2023, the U.S. FDA reviewed early-stage clinical data (Phase I and IIa) and provided written feedback on the design of Antev's planned Phase III trial for Teverelix, targeting patients with advanced prostate cancer and high cardiovascular risk—an area with significant unmet clinical need. Subsequently, in December 2023, the FDA approved a Phase IIb trial involving 40 patients with advanced prostate cancer. In November 2024, the agency also approved another Phase IIb study for acute urinary retention, set to enroll 390 patients. These regulatory milestones support Antev's broader strategy to advance Teverelix as a targeted therapy for patients with specific medical needs. The anticipated launch of these emerging therapies are poised to transform the GnRH receptor antagonists market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GnRH receptor antagonists market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about GnRH receptor antagonists clinical trials, visit @ GnRH Receptor Antagonists Treatment GnRH Receptor Antagonists Overview GnRH antagonists mark a notable improvement in androgen deprivation therapy (ADT) for treating hormone-sensitive prostate cancer. These drugs function by directly inhibiting GnRH receptors in the pituitary gland, which quickly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a rapid drop in testosterone levels. This direct mechanism avoids the initial testosterone surge, or 'flare', that is often seen with other forms of ADT. A major clinical benefit of GnRH antagonists is their swift action, with testosterone levels typically reaching castration thresholds within days. This rapid hormonal suppression is especially beneficial for patients with metastatic or symptomatic disease who require immediate control. Moreover, GnRH antagonists have shown better cardiovascular safety compared to traditional treatments. For instance, the HERO trial demonstrated that relugolix, a once-daily oral GnRH antagonist, significantly reduced the risk of major cardiovascular events. As a result, these agents are particularly advantageous for patients with existing heart-related conditions. GnRH Receptor Antagonists Epidemiology Segmentation The GnRH receptor antagonists market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for GnRH Receptor Antagonist Total Eligible Patient Pool for GnRH Receptor Antagonist in Selected Indications Total Treated Cases in Selected Indications for GnRH Receptor Antagonist GnRH Receptor Antagonists Report Metrics Details Study Period 2020–2034 GnRH Receptor Antagonists Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Endometriosis, fibroids, prostate cancer, and others Key GnRH Receptor Antagonist Companies Debiopharm, Tiumbio, Antev, Ferring Pharmaceuticals, Sumitomo Pharma, Theramex, Kissei, and others Key GnRH Receptor Antagonists Debio 4326, Merigolix (TU2670), Teverelix, FIRMAGON, ORGOVYX, YSELTY, and others Scope of the GnRH Receptor Antagonists Market Report GnRH Receptor Antagonists Therapeutic Assessment: GnRH Receptor Antagonists' current marketed and emerging therapies GnRH Receptor Antagonists Market Dynamics: Conjoint Analysis of Emerging GnRH Receptor Antagonists Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, GnRH Receptor Antagonists Market Access and Reimbursement Discover more about GnRH receptor antagonists in development @ GnRH Receptor Antagonists Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of GnRH Receptor Antagonist 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 GnRH Receptor Antagonist Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2024 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2024 6. Market Share (%) Distribution by Indications in 2034 7 GnRH Receptor Antagonist: Background and Overview 7.1 Introduction 7.2 Treatment 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.4 Total Cases in Selected Indications for GnRH Receptor Antagonist in the 7MM 8.5 Total Eligible Patient Pool for GnRH receptor antagonist in Selected Indications in the 7MM 8.6 Total Treated Cases in Selected Indications for GnRH Receptor Antagonist in the 7MM 9 Marketed Therapies 9.1 Key Competitors 9.2 FIRMAGON (degarelix): FERRING PHARMACEUTICALS 9.2.1 Product Description 9.2.2 Regulatory milestones 9.2.3 Other developmental activities 9.2.4 Clinical development 9.2.5 Safety and efficacy 9.3 ORGOVYX (relugolix): Sumitomo Pharma List to be continued in the report 10 Emerging Therapies 10.1 Key Competitors 10.2 Debio 4326: Debiopharm 10.2.1 Product Description 10.2.2 Other developmental activities 10.2.3 Clinical development 10.2.4 Safety and efficacy 10.2.5 Analyst Views 10.3 Teverelix: Antev List to be continued in the report 11 GnRH Receptor Antagonist: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook 11.3 Conjoint Analysis 11.4 Key Market Forecast Assumptions 11.4.1 Cost Assumptions and Rebates 11.4.2 Pricing Trends 11.4.3 Analogue Assessment 11.4.4 Launch Year and Therapy Uptakes 11.5 Total Market Size of GnRH receptor antagonist in the 7MM 11.6 Market Size of GnRH Receptor Antagonist by Indication in the 7MM 11.7 Market Size of GnRH Receptor Antagonist by Therapies in the 7MM 11.8. The United States Market Size 11.8.1 Total Market Size of GnRH Receptor Antagonists in the United States 11.8.2 Market Size of GnRH Receptor Antagonist by Therapies in the United States 11.9 EU4 and the UK Market Size 11.10 Japan Market Size 12 Market Access and Reimbursement 13 SWOT Analysis of GnRH Receptor 14 KOL Views of GnRH Receptor 15 Unmet Needs of GnRH Receptor 16 Bibliography 17 Report Methodology Related Reports Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. Prostate Cancer Pipeline Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others. Endometriosis Market Endometriosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis companies, including Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon, among others. Uterine Fibroids Market Uterine Fibroids Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uterine fibroids companies, including AbbVie Inc., Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc., Takeda Pharmaceutical Company Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Freeit Data Solutions Ranks No. 3623 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
With Three-Year Revenue Growth of 106.05% Percent, This Marks Freeit Data Solution's 9th Time on the List AUSTIN, Texas, Aug. 13, 2025 /PRNewswire/ — Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that Freeit Data Solutions is No. 3623 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. Freeit Data Solutions is known for steady growth, exceptional customer care, and a commitment to delivering impactful IT solutions. Trusted by public and private sector organizations alike, Freeit provides a full range of IT infrastructure and cybersecurity services. With deep expertise and a people-first approach, we help customers tackle today's digital challenges with greater security, efficiency, and confidence. 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' For the full list, company profiles, and a searchable database by industry and location, visit: About Freeit Data Solutions Freeit Data Solutions is an Austin-based IT services and solutions company that designs and deploys data center solutions for mid to large-sized companies, enabling them to better manage and protect their data. For more information, visit: Follow Freeit Data Solutions: LinkedIn and Twitter.
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK, Aug. 13, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the 'Class Period'). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025. So What: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Altimmune class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Details of the case: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to the results of Altimmune's IMPACT Phase 2b MASH trial. In truth, Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint. Altimmune had consistently touted its inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial, while concealing higher responses in the placebo group, which they knew or should have known would negatively impact the topline results. Altimmune's IMPACT Phase 2b MASH trial results fell short of reality, as shown by Altimmune's topline data, which show that the statistical significance was not achieved for the fibrosis reduction primary endpoint. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Altimmune class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@
